Get the Stockscreener App
165.76
2.68%
-4.56
Icon Plc stock is traded at $165.76, with a volume of 757.70K.
It is down -2.68% in the last 24 hours and up +4.80% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$170.32
Open:
$173.86
24h Volume:
757.70K
Relative Volume:
0.67
Market Cap:
$12.79B
Revenue:
$8.27B
Net Income/Loss:
$173.28M
P/E Ratio:
76.34
EPS:
2.1712
Net Cash Flow:
$785.90M
1W Performance:
-2.49%
1M Performance:
+4.80%
6M Performance:
-11.22%
1Y Performance:
-15.00%
1-Day Range:
$165.58
$173.89
1-Week Range:
$162.18
$182.97
52-Week Range:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
165.76 | 12.79B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
What Just Happened at ICON (ICLR) and Why Did Shares Soar - Kavout | AI
ICLR|ICON PLC|Price:170.260|Chg%:+2.980 - TradingKey
ICON PLC (ICLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Hybrid Clinical Research Job at ICON plc | Apply Online Now! - BioTecNika
ICLR: Icon Plc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Earnings Preview: Icon PLC to Report Financial Results Post-market on July 29 - 富途牛牛
Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
ICON Plc (ICLR) is Strengthening After Challenges - Yahoo Finance
ICON Schedules Second Quarter 2026 Earnings Conference Call - BioSpace
ICON Schedules Second Quarter 2026 Earnings C - Moomoo
ICON plc to announce Q2FY26 results on July 29 - scanx.trade
ICON plc (NASDAQ: ICLR) schedules Q2 2026 earnings results call - Stock Titan
Press Release: ICON Schedules Second Quarter 2026 Earnings Conference Call - Moomoo
Icon defends claim it left investors with ‘billions in losses’ - The Times
ICON plc Q1 2026 Earnings: EPS Beat Lifts Results, Yet Stock Declines 1.21%Earnings Call Q&A - dars.gov.et
ICON PLC : Leerink Partners Raises Target Pri - Moomoo
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline - Yahoo Finance
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
ICON Plc (ICLR) Stock Analysis: A Healthcare Giant With 7.81% Potential Upside - DirectorsTalk Interviews
ETFs Investing in ICON Plc Stocks - TradingView
Icon reiterates 2026 guidance of $7.85B-$8.15B revenue and $10-$11 EPS amid 1.42x net book-to-bill - MSN
Prosight Management, LP's Icon PLC(ICLR) Holding History - GuruFocus
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm - mydailyrecord.com
ICON plc shares drop after internal probe into accounting practices announced - Pluang
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
RBC Capital Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $185 - 富途牛牛
ICON Stock and the CRO Trends Shaping Its Next Growth Phase - The Globe and Mail
ICON plc highlights its position in global clinical research. The Nasdaq-listed group continues to b - Ad-hoc-news.de
ICON Public Limited Company (ICLR) Fell Due to Uncertainty Surrounding Reported Earnings - Yahoo Finance
ICON plc outlines its role in global clinical research as a Nasdaq-listed CRO - ad-hoc-news.de
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset? - TradingView
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base - TradingView
Icon PLC | 3: Initial statement of beneficial ownership of securities- O'Neill Julie - Moomoo
ICON shares rise as earnings beat and CEO flags strong booking momentum - MSN
ICLRIcon Plc Options - Finviz
ICON plc. Shares trade on Nasdaq amid steady business backdrop. - AD HOC NEWS
Icon Q1 2026 Earnings Call Transcript - MarketBeat
ICON Plc Financial Disclosures & Filings - TradingView
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $207 - Moomoo
Truist Financial Upgrades Icon PLC(ICLR.US) to Buy Rating, Announces Target Price $207 - Moomoo
Truist Upgrades ICON to Buy From Hold, Raises Price Target to $207 From $159, Cites Stronger Bookings, Improving Margin Visibility - Moomoo
Truist upgrades ICON stock rating on strong business wins By Investing.com - Investing.com South Africa
Icon PLC Company Profile & Introduction - Moomoo
Icon PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Shs Actuals & Estimates (BMFBOVESPA:ICLR34) - TradingView
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Raises Target Price to $190 - Moomoo
ICLR Maintained by Mizuho -- Price Target Raised to $190 - GuruFocus
ICON (ICLR) Slides as Investors Stay Cautious Ahead of Delayed Results Tied to Accounting Review - Moomoo
Icon PLC (ICLR) Shares Surge 5.5% -- What GF Score of 87 Tells I - GuruFocus
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $187 to $197 - Moomoo
Meeting Sites Where They Are: A Connected, Intelligence-Powered Operating Model - Fierce Pharma
Accounting restatement, big impairments and AGM plans at ICON plc (NASDAQ: ICLR) - Stock Titan
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):